Safety and Efficacy of SYM-SV/DS-002 in Patients With Severe Aortic Stenosis

• Sponsor: Medico's Hirata Inc. (Other)
• Overall Status: Terminated
• CT.gov ID: NCT03004599
• Collaborator: (none)
• Enrollment: 11
• Locations: 5
• Arm: 1
• Actual Duration (Months): 11
• Patients Per Site: 2.2
• Patients Per Site Per Month: 0.2

Study Details

Study Description

Brief Summary

Safety and Efficacy of SYM-SV/DS-002 in Patients with Severe Aortic Stenosis

Condition or Disease	Intervention/Treatment	Phase
Severe Aortic Stenosis	Device: SYM-SV-002 Aortic Bioprosthesis and SYM-DS-002 Transfemoral Delivery System	N/A

Detailed Description

To evaluate the safety and efficacy of Transfemoral Transcatheter Aortic Valve Implantation using SYM-SV-002 Aortic Bioprosthesis and SYM-DS-002 Transfemoral Delivery System in patients presenting with symptomatic severe aortic stenosis and with difficulty to safely undergo conventional surgical aortic valve replacement (AVR)

Study Design

• Study Type: Interventional
• Actual Enrollment: 11 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Safety and Efficacy of SYM-SV/DS-002 in Patients With Severe Aortic Stenosis
• Actual Study Start Date: Nov 1, 2016
• Actual Primary Completion Date: Oct 1, 2017
• Actual Study Completion Date: Oct 1, 2017

Arms and Interventions

Arm	Intervention/Treatment
Other: Transcatheter Aortic Valve Implantation (TAVI)	Device: SYM-SV-002 Aortic Bioprosthesis and SYM-DS-002 Transfemoral Delivery System; Transcatheter Aortic Valve Implantation via Transfemoral Approach; Other Names: ACURATE neo™ Aortic Bioprosthesis ACURATE TF™ Transfemoral Delivery System

Outcome Measures

Primary Outcome Measures

1. Survival rate [at 12 months post-procedure]

Secondary Outcome Measures

1. Occurrence rates of MACCE [at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years and 5 years post-procedure]

   MACCE is defined as a composite of: All Cause Mortality Myocardial infarction (MI) All Stroke Reintervention

2. Occurrence rates of individual MACCE components [at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years and 5 years post-procedure]

   Individual MACCE components include: All Cause Mortality Myocardial infarction (MI) All Stroke Reintervention

3. Occurrence rates of Major Adverse Events (MAEs) [at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years and 5 years post-procedure]

   MAEs include: MACCE Acute Kidney Injury (AKI) Cardiac Tamponade Prosthetic Valve Dysfunction (PVD) Cardiogenic Shock Prosthetic Valve Endocarditis Life-Threatening, Disabling or Major Bleeding Major Vascular Complications Cardiac Perforation Device Migration/Valve Embolism

4. Occurrence rate of conduction disturbance requiring Permanent Pacemaker Implantation(PPI) [at 1 month, 6 month, 12 months, 2 years, 3 years, 4 years and 5 years post-procedure]

5. Change in NYHA class from baseline [at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years and 5 years post-procedure]

6. Change in distance walked during 6-Minute Walk Test (6MWT) from baseline [at 1 month and 12 month post-procedure]

7. Change in QOL from baseline [at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years and 5 years post-procedure]

   Kansas City Cardiomyopathy Questionnaire (KCCQ)

8. Change in QOL from baseline [at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years and 5 years post-procedure]

   SF-36

9. Echocardiographic assessment of valve performance [at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years and 5 years post-procedure]

   Effective Orifice Area Index (EOAI)

10. Echocardiographic assessment of valve performance [at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years and 5 years post-procedure]

    Mean gradient

11. Echocardiographic assessment of valve performance [at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years and 5 years post-procedure]

    Degree of Aortic valve Regurgitation (AR) (Transvalvular and Paravalvular)

12. Echocardiographic assessment of valve performance [at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years and 5 years post-procedure]

    Left ventricular ejection fraction (LVEF)

13. Device success [Number of days from admission to discharge (estimated to be at 7 days post-procedure on average)]

    Device success is defined as that all of the following are achieved: Successful vascular access Successful delivery and deployment of the device Successful retrieval of the delivery system Correct position of the device in the proper anatomical location (placement in the aortic annulus with no impedance on device function) Intended performance of the prosthetic heart valve is confirmed by echocardiography (defined as below): No Patient-Prosthesis Mismatch (PPM) (EOAI >0.85cm2/m2) And mean aortic valve gradient < 20 mmHg or peak velocity < 3 m/sec, And no moderate or severe prosthetic valve regurgitation Only one valve implanted in the proper anatomical location

14. Procedural success [Number of days from admission to discharge (estimated to be at 7 days post-procedure on average)]

    Procedural success is defined as that all of the following are achieved: Achievement of the device success Absence of in-hospital MACCE

15. Occurrence rate of Prosthetic Valve Dysfunction (PVD) [at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years and 5 years post-procedure]

    Prosthetic Valve Dysfunction (PVD) is defined as: Aortic regurgitation (AR) reported as moderate or severe by echocardiography assessments Significant aortic stenosis (AS) which meets one or more of the following by echocardiography assessments: Peak velocity > 4 m/s Mean gradient > 35 mmHg Effective Orifice Area (EOA) < 0.8 cm2 TVIV1／TVIV2 < 0.25

16. Occurrence rate of clinical endpoints per VARC 2 [at 1 month post-procedure]

    Mortality Stroke Myocardial infarction (MI) Bleeding complications Acute kidney injury (AKI) Vascular complications Conduction disturbances and arrhythmia Other TAVI-related complications

Eligibility Criteria

Criteria

• Ages Eligible for Study: N/A and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

1. At least one cardiologist and one cardiac surgeon agree that it is difficult for the patient to receive a surgical procedure due to medical factors such that the subject has various comorbidities and he/she is more likely to die or suffer from severe diseases than to have significant improvements by a surgical procedure.

2. Subject has senile degenerative aortic valve stenosis with:

• mean gradient > 40 mmHg, or maximum jet velocity greater than 4.0 m/sec by either resting or dobutamine stress echocardiogram, or simultaneous pressure recordings at cardiac catheterization

• AND an initial aortic valve area of ≤ 0.8 cm2 (or aortic valve area index ≤ 0.5 cm2/m2) by resting echocardiogram or simultaneous pressure recordings at cardiac catheterization

1. Subject is symptomatic from his/her aortic valve stenosis (AS), as demonstrated by New York Heart Association (NYHA) Functional Class II or greater.

2. The subject has been informed of the nature of this trial, agrees to its provisions and has provided written informed consent as approved by the IRB of the respective clinical site.

3. The subject or the subject's legal representative agrees to visit the site where he/she receives index procedure for all required post-procedure follow-ups.

Exclusion Criteria:

1. Evidence of an acute myocardial infarction ≤ 30 days (The procedure day is counted as day 0.) before the implant procedure

2. Any percutaneous coronary or peripheral interventional procedures, including placements of bare metal stents are performed within 30 days prior to the implant procedure, or any drug eluting stents are placed within 6 months (One month is counted as 30 days.) prior to the implant procedure

3. Untreated clinically significant coronary artery disease (CAD) requiring revascularization

4. Blood dyscrasias as defined:

leukopenia (WBC < 1,000/mm3), thrombocytopenia (platelet count <50,000 cells/mm3), history of bleeding diathesis or coagulopathy

1. Cardiogenic shock manifested by low cardiac output, vasopressor dependence, or mechanical hemodynamic support

2. Need for emergency surgery for any reason

3. Severe ventricular dysfunction with left ventricular ejection fraction (LVEF) < 20% as measured by resting echocardiogram

4. Cerebrovascular accident (CVA) or transient ischemic attack (TIA) within 6 months prior to the implant procedure (except mild TIA related to aortic stenosis)

5. End stage renal disease requiring chronic dialysis or serum creatinine > 3.0 mg/dL

6. Active Gastrointestinal (GI) bleeding within 3 months prior to the implant procedure

7. A known hypersensitivity or contraindication to any of the following which cannot be adequately pre-medicated:

• Aspirin

• Heparin (HIT/HITTS)

• Nitinol (titanium or nickel)

• P2Y12 inhibitors (such as Ticlopidine etc.)

• Contrast media

1. Ongoing sepsis, including active endocarditis

2. Subject refuses a blood transfusion

3. Life expectancy < 12 months due to associated non-cardiac comorbid conditions

4. Other medical, social, or psychological conditions that in the opinion of a principal investigator or sub-investigator precludes the subject from appropriate consent

5. Severe dementia (unable to provide informed consent for the treatment/procedure, unable to live an independent life outside of a chronic care facility, or expected to be fundamentally unable to undergo rehabilitation after the procedure, or unable to come to the site for follow-up visits)

6. Currently participating in other trials of investigational drugs or other investigational devices

7. Native aortic annulus size < 21 mm or > 27 mm per the baseline diagnostic imaging

8. Pre-existing prosthetic heart valve and / or prosthetic ring in any position

9. Mixed aortic valve disease (aortic stenosis and predominant aortic regurgitation (3-4+))

10. Moderate to severe (3-4+) or severe (4+) mitral regurgitation or severe (4+) tricuspid regurgitation

11. Moderate to severe mitral stenosis

12. Hypertrophic obstructive cardiomyopathy

13. New or untreated echocardiographic evidence of intracardiac mass, thrombus or vegetation

14. Congenital bicuspid or unicuspid valve verified by echocardiograph

15. Extreme eccentric calcification of the native aortic valve

16. Transesophageal echocardiogram (TEE) is contraindicated.

17. Scheduled surgical or percutaneous procedure to be performed prior to 1-month visit post-implant procedure

18. Hepatic failure (Child C or more)

19. Aortic or peripheral condition NOT appropriate for transfemoral implant due to the size, disease and degree of calcification or tortuosity of the aorta or ilio-femoral arteries

20. Thoracic or abdominal aortic aneurysm

21. Woman who is pregnant, breastfeeding or willing to become pregnant

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Kokura Memorial Hospital	Kitakyushu	Fukuoka	Japan	802-8555
2	Osaka University Hospital	Suita	Osaka	Japan	565-0871
3	Sakakibara Heart Institute	Fuchu	Tokyo	Japan	183-0003
4	Teikyo University Hospital	Itabashi	Tokyo	Japan	173-8606
5	Keio University Hospital	Shinjuku	Tokyo	Japan	160-8582

Sponsors and Collaborators

• Medico's Hirata Inc.

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Medico's Hirata Inc.
• ClinicalTrials.gov Identifier: NCT03004599
• Other Study ID Numbers: MH-P-002
• First Posted: Dec 29, 2016
• Last Update Posted: Nov 6, 2017
• Last Verified: Nov 1, 2017

• Keywords provided by Medico's Hirata Inc.: Valvular Heart Disease; Critical Aortic Stenosis; Severe Aortic Stenosis; High Risk; Aortic Valve Replacement; Cardiovascular Disease; Aortic Stenosis; Heart Valve Therapy; Transcatheter; Transfemoral; TAVI; TAVR; ACURATE neo™ Aortic Bioprosthesis; ACURATE TF™ Transfemoral Delivery System
• Additional relevant MeSH terms: Aortic Valve Stenosis; Constriction, Pathologic

Study Results

No Results Posted as of Nov 6, 2017